RxDoctor Payments Data

Mohammad El Sayyad, MD

Family Medicine · Maumee, OHNPI 1629243878

Payments from drug & device makers

$356in general payments, 2019–2025

Across 17 payments — averaging $20.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$138
  • Medtronic$127
  • Novartis$40
  • AstraZeneca$27
  • Eisai Inc.$12
  • Novo Nordisk$12

What the payments were for

  • Food & beverage$356100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)9$138
Medtronic3$127
Novartis2$40
AstraZeneca1$27
Eisai Inc.1$12
Novo Nordisk1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$356 in reported general payments places this provider in the 45th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$262,432
Medicare patients
653
Services billed
4,430

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide99$135,061
EliquisApixaban94$102,177
JanuviaSitagliptin Phosphate66$72,997
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog18$40,821
JardianceEmpagliflozin32$36,185
TrulicityDulaglutide24$30,111
MounjaroTirzepatide23$26,183
Tresiba Flextouch U-200Insulin Degludec12$24,412
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog57$23,714
XareltoRivaroxaban24$22,232
MyrbetriqMirabegron17$20,614
Victoza 3-PakLiraglutide16$18,711
Spiriva RespimatTiotropium Bromide21$17,505
Spiriva HandihalerTiotropium Bromide25$15,569
Tiotropium Bromide12$11,438

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$12$135,06199 claims
AstraZenecaSymbicort$27$4,50815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Maumee

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →